Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 121–130 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 121
- Medicine slug
- armodafinil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
42 L
- Numeric value
- 42
- Unit
- L
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facd329b-1925-61df-e053-6294a90ab738 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2f0921-e791-426c-9192-2b7162e2158c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cac300-c3d2-4189-a410-2aaf3773c090 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbe7c0d9-dfd2-4000-bd76-7fe3454ce64f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd49302-f757-d945-e063-6294a90afcba (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution NUVIGIL has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23da56b8-7552-4362-a1ab-e794c131194c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1ba1cdd-cf57-7a8c-e053-2a95a90a2c19 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4128759d-ed7c-4130-b24c-a0541f2b9e7f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d878aed0-ddbf-8fa1-abf7-d3e480260845 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution NUVIGIL has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98338994-7818-4b86-ae98-cd08fa700879 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69631d0-1263-769e-b232-4ab9160e0fa3 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution NUVIGIL has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3341ec8-1ad4-49e2-922b-13d1b30c8c1d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0799f7-7644-4057-a7da-75436f978c61 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e33a21-7816-4fa9-9fc7-c559426ad2b9 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Distribution Armodafinil has an apparent volume of distribution of approximately 42 L.
Projected row 122
- Medicine slug
- arsenic-trioxide
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 35
- Source count
- 19
- Agreement rate
- 0.789474
- Recorded readings
10 to 14 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb52683-1e74-4831-a771-55a78536cfe5 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dddfe9e-06bf-4983-9c55-71b19da8fcdc (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e2107c-26c3-40fc-978e-0ba5b84098ac (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8849c8f9-ee41-4ccd-8a62-67b04e80a276 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a999752-f350-4eff-97e7-e7106dfa85b5 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d921f52f-2f38-4300-ae40-31f00b3a500a (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:101fc347-d0ad-4aee-8b06-9feb187fd741 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5845022e-8c01-451b-ae49-a28e58c5f845 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a482eccd-8837-47ea-904d-2f2c294d10fa (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b007d59-99ad-409f-a71e-7f4e7d6f6b12 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c99b01b4-67ff-4793-8375-fe3a21c6c9be (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48388282-3768-4309-8982-2766cbc9fd59 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b2a7ed9-5ed3-42fc-b19b-d50700396233 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fe0fe9f-e87b-44ab-b92c-9b3d23942063 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9008658-c2dd-49f4-b1c4-26e232c81957 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae5cae02-ca57-4da5-8940-81253fdb8679 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 hours to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1ad5d87-e65e-402f-86b5-e641fc4e61ab (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 hours to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e1d2b63-ccb2-4e97-a009-5983eabf65e4 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 hours to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d27f88-de82-4379-b143-4b94b3dd8bbe (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Plasma concentration of As III declined in a biphasic manner with a mean elimination half-life of 10 hours to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase.
Projected row 123
- Medicine slug
- arsenic-trioxide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 35
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
562 L
- Numeric value
- 562
- Unit
- L
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb52683-1e74-4831-a771-55a78536cfe5 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae5cae02-ca57-4da5-8940-81253fdb8679 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dddfe9e-06bf-4983-9c55-71b19da8fcdc (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e2107c-26c3-40fc-978e-0ba5b84098ac (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N = 10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8849c8f9-ee41-4ccd-8a62-67b04e80a276 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (Vss) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a999752-f350-4eff-97e7-e7106dfa85b5 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d921f52f-2f38-4300-ae40-31f00b3a500a (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1ad5d87-e65e-402f-86b5-e641fc4e61ab (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e1d2b63-ccb2-4e97-a009-5983eabf65e4 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:101fc347-d0ad-4aee-8b06-9feb187fd741 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5845022e-8c01-451b-ae49-a28e58c5f845 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a482eccd-8837-47ea-904d-2f2c294d10fa (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b007d59-99ad-409f-a71e-7f4e7d6f6b12 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c99b01b4-67ff-4793-8375-fe3a21c6c9be (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48388282-3768-4309-8982-2766cbc9fd59 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (Vss) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d27f88-de82-4379-b143-4b94b3dd8bbe (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b2a7ed9-5ed3-42fc-b19b-d50700396233 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fe0fe9f-e87b-44ab-b92c-9b3d23942063 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9008658-c2dd-49f4-b1c4-26e232c81957 (opens source in a new tab)
Arsenic Trioxide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution (V ss ) for As III is large (mean 562 L, N=10) indicating that As III is widely distributed throughout body tissues.
Projected row 124
- Medicine slug
- asenapine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
35%
- Numeric value
- 35
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf587c48-9cd2-4dc5-b0e9-21783c5633a6 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3512687b-d1c7-45c4-8822-3a2ad53575a5 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5429f134-839f-4ffc-9944-55f51238def8 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7a1b17-e73e-4417-a172-bfb03569d7ff (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5cd9abb-40e3-4cb5-a1b2-40cdba8a1c7e (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e1cc9f-7699-49ea-b179-acb65e162304 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
Projected row 125
- Medicine slug
- asenapine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 0.857143
- Recorded readings
24 hrs
- Numeric value
- 24
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf587c48-9cd2-4dc5-b0e9-21783c5633a6 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3512687b-d1c7-45c4-8822-3a2ad53575a5 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5429f134-839f-4ffc-9944-55f51238def8 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7a1b17-e73e-4417-a172-bfb03569d7ff (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5cd9abb-40e3-4cb5-a1b2-40cdba8a1c7e (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e1cc9f-7699-49ea-b179-acb65e162304 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
30 hours
- Numeric value
- 30
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:685eaf44-5944-4f38-afba-0a4fc0b3462b (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Following SECUADO removal, the apparent elimination half-life is approximately 30 hours.
Projected row 126
- Medicine slug
- asenapine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf587c48-9cd2-4dc5-b0e9-21783c5633a6 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single 5 mg dose of asenapine, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3512687b-d1c7-45c4-8822-3a2ad53575a5 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M 1 ). 12.3 Pharmacokinetics Following a single 5 mg dose of asenapine, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5429f134-839f-4ffc-9944-55f51238def8 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single 5 mg dose of SAPHRIS, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7a1b17-e73e-4417-a172-bfb03569d7ff (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8,128 nM for M 1 ). 12.3 Pharmacokinetics Following a single 5 mg dose of asenapine sublingual tablets, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5cd9abb-40e3-4cb5-a1b2-40cdba8a1c7e (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single 5 mg dose of asenapine sublingual tablets, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e1cc9f-7699-49ea-b179-acb65e162304 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single 5 mg dose of asenapine, the mean C max was approximately 4 ng/mL and was observed at a mean t max of 1 hour.
Projected row 127
- Medicine slug
- asenapine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
20 to 25 L/kg
- Numeric value
- 20
- Unit
- L/kg
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf587c48-9cd2-4dc5-b0e9-21783c5633a6 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 to 25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3512687b-d1c7-45c4-8822-3a2ad53575a5 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution : Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5429f134-839f-4ffc-9944-55f51238def8 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:685eaf44-5944-4f38-afba-0a4fc0b3462b (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution Asenapine is rapidly distributed and has a large volume of distribution (approximately 20-25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7a1b17-e73e-4417-a172-bfb03569d7ff (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5cd9abb-40e3-4cb5-a1b2-40cdba8a1c7e (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e1cc9f-7699-49ea-b179-acb65e162304 (opens source in a new tab)
Asenapine label
Version not recorded · Effective date not recorded
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 to 25 L/kg), indicating extensive extravascular distribution.
Projected row 128
- Medicine slug
- atazanavir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
12.1 hours
- Numeric value
- 12.1
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbea274-d6b5-4faa-bbf0-05fefab42114 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:165cff62-b284-4a27-a65d-9ec8a5bfcdd8 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a0c609f-e296-4925-a35c-e93a04467655 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654b7e08-33d8-47e7-b37f-3681e79c7b8b (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c98e40ec-8a2c-4f19-b1c3-c82f708c2490 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants.
Projected row 129
- Medicine slug
- atazanavir
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbea274-d6b5-4faa-bbf0-05fefab42114 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1 Absorption Atazanavir is rapidly absorbed with a T max of approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:165cff62-b284-4a27-a65d-9ec8a5bfcdd8 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1 Absorption Atazanavir is rapidly absorbed with a T max of approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a0c609f-e296-4925-a35c-e93a04467655 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1 Absorption Atazanavir is rapidly absorbed with a T max of approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654b7e08-33d8-47e7-b37f-3681e79c7b8b (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1 Absorption Atazanavir is rapidly absorbed with a T max of approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c98e40ec-8a2c-4f19-b1c3-c82f708c2490 (opens source in a new tab)
Atazanavir label
Version not recorded · Effective date not recorded
Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1 Absorption Atazanavir is rapidly absorbed with a T max of approximately 2.5 hours.
Projected row 130
- Medicine slug
- atenolol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 95
- Source count
- 95
- Agreement rate
- 1
- Recorded readings
6 to 7 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 95
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 95 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b335b4-93d2-0459-e053-2a95a90a1a5b (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee143f2f-be60-bc67-e053-2a95a90ae6e6 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d70576a-6fa7-481d-e054-00144ff88e88 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b8a4689-3916-4f4b-b54a-bbb4e322d79b (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:754a1ea1-1233-066f-e053-2991aa0a33a9 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67d9ca94-2af6-4ebb-a5c3-8d360f741277 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09b21985-1818-449d-9b29-98f733cf7b9f (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdca0ef8-2ac3-4430-a662-f88522f68d8e (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76d03b8-f8d6-59b8-e053-6394a90a3a3f (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ad1426a-5a74-427b-812d-c7b144c84474 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ad0c7dd-e4e5-4968-9372-7a9bb30073ec (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:746db603-a6e1-4dc3-c2d8-92314419098c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral TENORMIN is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fadc652-b075-46ec-ae05-beaf7d91ae13 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9db36b04-f353-55d6-e053-2a95a90ae08f (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cdc2ed-99bf-0d6a-e053-2a95a90a0262 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3a23869-1e3f-40f0-9726-833700580113 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd0f7f1c-dd20-4de6-a012-f581a216f23f (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4ece8f4-3714-42ba-b36d-d00586dfd33a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f8304a4-93de-774f-e053-2a91aa0aa5b5 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbf6779-8e9b-4ce1-a361-ede4914dd2f3 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d6ea66b-30ef-4829-b757-5ea9d412a666 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecfcebcc-8fcd-48e6-871e-151074df3abc (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f1f3f4-bbda-458b-b15f-d942c90534e2 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba0b0221-d4b3-4cb1-9435-53a75fcc4b40 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db801706-1362-44c7-92ab-f584f96c7e1c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23e96396-85d3-0d8e-e063-6394a90a614d (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd43e0b1-c05e-01ae-e053-2a95a90af1cd (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fe1a12-a6d5-4c4c-9d77-6f717b43f8fe (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5bd8e2-1314-0f7f-e053-2995a90ae86e (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c86a73-70b6-46b2-ad9a-272c8d4673e9 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ee7b7da-303d-4a57-a1eb-25e8923660c0 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35d04cfd-34d4-429c-b990-a6c00137bc77 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15c0c2df-f195-45f9-a1e4-1ed2a43c2216 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e850b1e-28a4-4ff8-8ed7-bb0b29faa28a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral TENORMIN is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f682a775-2255-05e2-e053-2a95a90ac3f3 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dd93a47-d14c-49be-9c22-97c0cdbec75a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c8d507-e040-409e-9f97-742925cc66a1 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d73a475a-c8c9-44a0-89ac-6a2d665c0d24 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79490e9f-bbed-4e8f-b640-7d218741303a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:741f328d-21a1-3b19-e053-2a91aa0aa327 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d19e9fcf-dfa1-43d7-94dc-e3f03fb90f5c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4555261d-a997-4aa5-aba8-81aac7033787 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95761173-1c95-46b2-a08f-fbc3e70daba8 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdb229-928b-4c22-88f1-f4dd97cde274 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c69b8e5e-c7c3-4883-9cea-f7f435a8ede8 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78d394b8-8ffb-a846-e053-2991aa0aa58c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ca8dd77-cdac-41fe-a742-b1b32551203b (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f418e6-47db-6a71-e063-6294a90a632c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f419c72e-f1f9-4b5a-94ff-a525367cdce4 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25a72ec9-de0f-44e5-90b8-da1aab0d3588 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec7b937-e448-45c7-ad7a-55fd722a50a6 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:722d6532-20d0-4936-ae9c-b7bb593b960a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:331128cc-f56e-4329-e063-6394a90a5ead (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70d7a585-7a46-4eac-b2b5-2ac5b98d9882 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4f06c00-9024-4e04-a882-0da2b24d8ff7 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f318707a-4fb9-604c-e053-2a95a90ae973 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43acd912-f0f4-47eb-b81f-cbbfed77c557 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:239b1cce-3b1a-f049-e063-6394a90a0e0a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a54656e-60dd-4ffc-b01a-423af19cd618 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e115f27a-6a7c-498c-b4a1-2d4c5716af22 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b198b34c-861a-4b52-b4df-8c48b807520a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:247569d6-9a73-f1d0-e063-6394a90a667a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fc4a969-286f-4fd2-b16a-f0291fd1c5c0 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f744371-94fa-419d-bfed-b22301dde8b8 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96dd038f-b363-4e24-9c67-82b7c85c3bc4 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c757de-1cbf-61f5-e053-2995a90accfc (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35d99c43-7305-4a4a-886e-a9bf3ee88fa8 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7a8830a-5eda-4f0e-bf03-61ee8ed6558d (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8115a2bc-69aa-60b4-e053-2a91aa0aeae7 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82100fc8-5a5a-4d80-8101-72024ee0abef (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9aef7a49-d21f-4529-8abf-68bdc343bb6c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0e3b2a5-5ea1-4549-8144-bd059f7966f0 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7366c6f8-4cb3-520e-e053-2991aa0a2cc8 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ae158bb-aa03-4b44-916b-1fcfc84b4fd0 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d35592c-91ac-44f6-b077-5963e952f0dd (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410c48ae-582a-2ab2-e063-6294a90af27c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98d29958-b026-4888-a516-7bb85bb7d479 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d21f2b4d-6584-48e5-8045-e5927ba03329 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26d3df38-20c6-40e0-a456-da4f10fff632 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7048c81-6769-436b-8397-fbaa7489fcdf (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50760735-9305-0bbf-e063-6294a90a5b4c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02b4be4-b75c-4153-b402-cf330a077439 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5126a70e-632d-e626-e063-6394a90ab791 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8cdb347-1767-4595-baff-b50987cd8c3a (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8d48a47-ccab-4a35-a092-6e562683ade3 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f31b11ed-2ff6-5cfc-e053-2a95a90af2ca (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3e72119-e3c3-41ba-8787-acc86b44d6c4 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98471493-56ee-47a4-9120-0975c265361e (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73671d55-3e10-cb1d-e053-2991aa0ac038 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3d9f826-7ed7-1e3b-e053-2995a90ae731 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol tablets is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:897e18f6-3b57-4ef0-85ff-9dfa23521eb9 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:290f4de3-8815-466c-81dc-8bc632375896 (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7a93c64-0c52-4d72-a9be-37c7ca355cdf (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50762eee-e139-4d7f-e063-6294a90a777c (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8501f6c1-8157-4189-e053-2a91aa0ac4ef (opens source in a new tab)
Atenolol label
Version not recorded · Effective date not recorded
The elimination half-life of oral atenolol is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=120Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.